Formulation and optimization of spray-dried amlodipine solid dispersion for enhanced oral absorption

Drug Development and Industrial Pharmacy

Volumn 39, Issue 7, 2013, Pages 1133-1141

  Jang, Dong Jin ^a   Sim, Taeyong ^a   Oh, Euichaul ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Amlodipine; Dextrin; Dissolution rate; Oral absorption; Permeability; Solid dispersion

Indexed keywords

AMLODIPINE; DEXTRIN;

ARTICLE; DISPERSION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG PENETRATION; DRUG SOLUBILITY; DRUG STABILITY; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PROCESS OPTIMIZATION; RAT; ROOM TEMPERATURE; SPRAY DRYING;

ABSORPTION; ADMINISTRATION, ORAL; AMLODIPINE; ANIMALS; CACO-2 CELLS; CALCIUM CHANNEL BLOCKERS; CHEMISTRY, PHARMACEUTICAL; DRUG STABILITY; HUMANS; MALE; PERMEABILITY; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY;

EID: 84878829297     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2012.723218     Document Type: Article

References (48)

1. de Champlain J, Karas M, Nguyen P, Cartier P, Wistaff R, Toal CB et al. (1998). Different effects of nifedipine and amlodipine on circulating catecholamine levels in essential hypertensive patients. J Hypertens, 16:1357-1369.
2. Humphreys A, Boersig C. (2003). Cholesterol drugs dominate. Med Ad News, 22:42-57.
3. Rovnyak GC, Atwal KS, Hedberg A, Kimball SD, Moreland S, Gougoutas JZ, O'Reilly BC, Schwartz J, Malley MF. (1992). Dihydropyrimidine calcium channel blockers. 4. Basic 3-substituted-4-aryl-1, 4-dihydropyrimidine-5-carboxylic acid esters. Potent antihypertensive agents. J Med Chem, 35:3254-3263.
4. Amidon GL, Lennernäs H, Shah VP, Crison Jr. (1995). A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res, 12:413-420.
5. Rausl D, Fotaki N, Zanoski R, Vertzoni M, Cetina-Cizmek B, Khan MZ et al. (2006). Intestinal permeability and excretion into bile control the arrival of amlodipine into the systemic circulation after oral administration. J Pharm Pharmacol, 58:827-836.
6. Boetker JP, Savolainen M, Koradia V, Tian F, Rades T, Müllertz A et al. (2011). Insights into the early dissolution events of amlodipine using UV imaging and Raman spectroscopy. Mol Pharm, 8:1372-1380.
7. Meredith PA, Elliott HL. (1992). Clinical pharmacokinetics of amlodipine. Clin Pharmacokinet, 22:22-31.
8. Abernethy DR. (1992). Pharmacokinetics and pharmacodynamics of amlodipine. Cardiology, 80 Suppl 1:31-36.
9. Beresford AP, Macrae PV, Stopher DA. (1988). Metabolism of amlodipine in the rat and the dog: a species difference. Xenobiotica, 18:169-182.
10. Jang DJ, Jeong EJ, Lee HM, Kim BC, Lim SJ, Kim CK. (2006). Improvement of bioavailability and photostability of amlodipine using redispersible dry emulsion. Eur J Pharm Sci, 28:405-411.
11. Meredith PA. (2009). Potential concerns about generic substitution: bioequivalence versus therapeutic equivalence of different amlodipine salt forms. Curr Med Res Opin, 25:2179-2189.
12. Saigal N, Baboota S, Ahuja A, Ali J. (2008). Fast-dissolving intra-oral drug delivery systems. Exp Opin Ther Pat, 18:769-781.
13. Ragno G, Garofalo A, Vetuschi C. (2002). Photodegradation monitoring of amlodipine by derivative spectrophotometry. J Pharm Biomed Anal, 27:19-24.
14. Ragno G, Cione E, Garofalo A, Genchi G, Ioele G, Risoli A et al. (2003). Design and monitoring of photostability systems for amlodipine dosage forms. Int J Pharm, 265:125-132.
15. Cho SH, Youn YS, Jung YT, Park CS, Lee HK, Lee KH, Jeong EJ, Kim YH, Jin HT, Cheon JH. (2005). Organic acid salt of amlodipine. Patents US6890944.
16. Furlan B, Copar A, Jeriha A. (1995). Process for the preparation of amlodipine benzenesulphonate. Patent US5438145.
17. Lemmens JM, Peters THA, Benneker FBG, Picha F. (2003). Amlodipine fumarate. Patent US6518288.
18. Park YJ, Kang DS, Ju SY. (2005). A composition of fast dissolving tablets containing amlodipine free base. Patent KR2005-0035907.
19. Yang GU, Gil YS, Hong SC, Yuu CH, Ahn KY, Ahn KS. (2006). Composition for oral administration of amlodipine freebase which has improved stability and processability. Patent KR 2005-0052738.
20. Ahuja N, Katare OP, Singh B. (2007). Studies on dissolution enhancement and mathematical modeling of drug release of a poorly water-soluble drug using water-soluble carriers. Eur J Pharm Biopharm, 65:26-38.
21. Aggarwal AK, Singh S. (2011). Physicochemical characterization and dissolution study of solid dispersions of diacerein with polyethylene glycol 6000. Drug Dev Ind Pharm, 37:1181-1191.
22. Fouad EA, EL-Badry M, Mahrous GM, Alanazi FK, Neau SH, Alsarra IA. (2011). The use of spray-drying to enhance celecoxib solubility. Drug Dev Ind Pharm, 37:1463-1472.
23. DiNunzio JC, Schilling SU, Coney AW, Hughey JR, Kaneko N, McGinity JW. (2012). Use of highly compressible Ceolus™ microcrystalline cellulose for improved dosage form properties containing a hydrophilic solid dispersion. Drug Dev Ind Pharm, 38:180-189.
24. Koradia V, Tenho M, Lopez de Diego H, Ringkjøbing-Elema M, Møller-Sonnergaard J, Salonen J et al. (2012). Investigation of solid phase composition on tablet surfaces by grazing incidence X-ray diffraction. Pharm Res, 29:134-144.
25. Chutimaworapan S, Ritthidej G, Oguchi T, Yamamoto K. (2000). Controlled release of nifedipine from microspheres spray dried with eudragit and polyvinylpyrrolidone. J Pharm Sci Tech, 60:196-206.
26. Sheen PC, Khetarpal VK, Cariola CM, Rowlings CE. (1995). Formulation studies of a poorly water-soluble drug in solid dispersions to improve bioavailability. Int J Pharm, 118:221-227.
27. Yamashita K, Nakate T, Okimoto K, Ohike A, Tokunaga Y, Ibuki R et al. (2003). Establishment of new preparation method for solid dispersion formulation of tacrolimus. Int J Pharm, 267:79-91.
28. Lee EJ, Lee SW, Choi HG, Kim CK. (2001). Bioavailability of cyclosporin A dispersed in sodium lauryl sulfate-dextrin based solid microspheres. Int J Pharm, 218:125-131.
29. Saito M, Nozawa Y, Sadzuka Y, Miyagishima A, Sonobe T, Nakajima T. (2001). Preparation and dissolution characteristics of griseofulvin solid dispersions with dextrin or starch. J Pharm Sci Technol, 61:11-20.
30. Saito M, Ugajin T, Nozawa Y, Sadzuka Y, Miyagishima A, Sonobe T. (2002). Preparation and dissolution characteristics of griseofulvin solid dispersions with saccharides. Int J Pharm, 249:71-79.
31. Kawabata Y, Yamamoto K, Debari K, Onoue S, Yamada S. (2010). Novel crystalline solid dispersion of tranilast with high photostability and improved oral bioavailability. Eur J Pharm Sci, 39:256-262.
32. Onoue S, Takahashi H, Kawabata Y, Seto Y, Hatanaka J, Timmermann B et al. (2010). Formulation design and photochemical studies on nanocrystal solid dispersion of curcumin with improved oral bioavailability. J Pharm Sci, 99:1871-1881.
33. Vasconcelos T, Sarmento B, Costa P. (2007). Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov Today, 12:1068-1075.
34. Ambike AA, Mahadik KR, Paradkar A. (2005). Spray-dried amorphous solid dispersions of simvastatin, a low tg drug: in vitro and in vivo evaluations. Pharm Res, 22:990-998.
35. Peltonen L, Valo H, Kolakovic R, Laaksonen T, Hirvonen J. (2010). Electrospraying, spray drying and related techniques for production and formulation of drug nanoparticles. Expert Opin Drug Deliv, 7:705-719.
36. Takeuchi H, Nagira S, Yamamoto H, Kawashima Y. (2004). Solid dispersion particles of tolbutamide prepared with fine silica particles by the spray-drying method. Powder Technol, 141:187-195.
37. Ho PY, Yeh TK, Yao HT, Lin HL, Wu HY, Lo YK et al. (2008). Enhanced oral bioavailability of paclitaxel by D-alpha-tocopheryl polyethylene glycol 400 succinate in mice. Int J Pharm, 359:174-181.
38. Carvalho M, Oliveira CH, Mendes GD, Sucupira M, Moraes ME, De Nucci G. (2001). Amlodipine bioequivalence study: quantification by liquid chromatography coupled to tandem mass spectrometry. Biopharm Drug Dispos, 22:383-390.
39. Rowe RC, Sheskey PJ, Owen SC. Handbook of pharmaceutical excipients. London: Pharmaceutical press, 2003:651-653.
40. Fukushima K, Terasaka S, Haraya K, Kodera S, Seki Y, Wada A et al. (2007). Pharmaceutical approach to HIV protease inhibitor atazanavir for bioavailability enhancement based on solid dispersion system. Biol Pharm Bull, 30:733-738.
41. Patel AR, Joshi VY. (2008). Evaluation of SLS: APG mixed surfactant systems as carrier for solid dispersion. AAPS PharmSciTech, 9:583-590.
42. Aungst BJ. (2000). Intestinal permeation enhancers. J Pharm Sci, 89:429-442.
43. Ganem-Quintanar A, Kalia Y, Falson-Rieg F, Buri P. (1997). Mechanisms of oral permeation enhancement. Int J Pharm, 156:127-142.
44. Mortelmans K, Haworth S, Lawlor T, Speck W, Tainer B, Zeiger E. (1986). Salmonella mutagenicity tests: II. Results from the testing of 270 chemicals. Environ Mutagen, 8 Suppl 7:1-119.
45. Chang Y, Scire J, Jacobs B. (1988). Effect of particle size and microstructure properties on encapsulated orange oil. Flavor encapsul, 370:87-102.
46. Sheu T, Rosenberg M. (1995). Microencapsulation by spray drying ethyl caprylate in whey protein and carbohydrate wall systems. J Food Sci, 60:98-103.
47. Shohin IE, Ramenskaya GV, Vasilenko GF, Malashenko EA. (2010). In vitro dissolution kinetics of amlodipine tablets marketed in Russia under biowaiver conditions. Dissolut Technol, 17:20-22.
48. Pokharkar VB, Mandpe LP, Padamwar MN, Ambike AA, Mahadik KR, Paradkar A. (2006). Development, characterization and stabilization of amorphous form of a low Tg drug. Powder Technol, 167:20-25.